BridgeBio Oncology Therapeutics Q3 2026 net loss narrows 24% to $34.2 million
BBOT•BridgeBio Oncology Therapeutics’ third-quarter 2026 net loss narrowed 24% year over year to $34.2 million. The company reported $315.3 million in cash, cash equivalents and marketable securities, with runway expected into 2029.
1. Quarterly results
Research and development expenses fell 16% year over year to $29.6 million, while general and administrative expenses dropped 44% to $7.9 million. Cash, cash equivalents and marketable securities totaled $315.3 million at September 30, with runway expected into 2029.
2. Clinical updates
BBO-8520 with pembrolizumab achieved a 75% objective response rate at 500 mg daily in patients with KRASG12C inhibitor-experienced non-small cell lung cancer. Monotherapy data updates for BBO-11818 and BBO-10203 are expected in the fourth quarter of 2026.
